Search for dissertations about: "PRRT"
Showing result 1 - 5 of 16 swedish dissertations containing the word PRRT.
-
1. Monitoring of neuroendocrine tumor patients undergoing systemic therapies
Abstract : Monitoring of neuroendocrine tumor (NET) patients undergoing systemic therapies is troublesome as biomarkers capable of detecting tumor responses have been difficult to establish. Changes in the sum of target lesion diameters are used to evaluate the effects of therapy according to the response evaluation criteria in solid tumors (RECIST 1.1). READ MORE
-
2. Theranostics in Neuroendocrine Tumors : Somatostatin Receptor Imaging and Therapy
Abstract : Neuroendocrine tumors (NETs) are characterized by cellular overexpression of somatostatin receptors (SSTR), which allows for the use of radiolabeled somatostatin analogs (SSA) for both imaging and therapy. Because NETs often are diagnosed at a metastatic stage, curative surgery is not possible. READ MORE
-
3. Nuclear medicine imaging and treatment in pheochromocytoma, paraganglioma, and role of the new tracer 11C-hydroxy ephedrine in diabetes mellitus
Abstract : Carbon-11 hydroxy ephedrine (11C-HED) is a norepinephrine analog which binds to the norepinephrine receptor present in adrenal medulla, lung, liver and pancreas. 11C-HED-positron emission tomography with concomitant computed tomography (PET/CT) can image these organs. READ MORE
-
4. Small-scale dosimetry methods for normal tissues after radioembolization and peptide receptor radiotherapies; a focus on the liver parenchyma and the bone marrow
Abstract : Radionuclide therapies are increasingly used in cancer treatments as they have been proven to be both effective and safe. As biodistributions and uptake vary widely between patients, a standardized approach is bound to leave a fraction of patients overtreated or undertreated. READ MORE
-
5. lmprovement of 177Lu-octreotate treatment of small-intestine neuroendocrine tumors by hyperfractionation
Abstract : Neuroendocrine tumor incidence is steadily rising, and the late diagnosis often results in metastatic disease and current treatments mostly prolong life and in-crease quality of life without increasing cure rate. 177Lu-octreotate was recently approved for treatment of neuroendocrine tumors, but the dosage scheme should be optimized. READ MORE